Study of targeted therapy for advanced ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study follows people with advanced ROS1-positive non-small cell lung cancer who are taking targeted therapy. It aims to understand how well the treatment works in real life and is for those who haven't had any prior treatment for their lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC).
- Your cancer is at an advanced stage (IIIB, IIIC, or IV).
- Your tumor has a specific gene change called a ROS1 fusion (confirmed by a special lab test).
- You have not had any previous treatment for your lung cancer, like chemotherapy, radiation, or surgery.
- You are at least 18 years old and feel well enough to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This clinical trial tests a new targeted therapy pill (repotrectinib) for people with ROS1-positive lung cancer that has spread to the brain. The pill is designed to enter the brain and attack cancer cells that other targeted treatments may not reach well.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This study tracks how well and safely repotrectinib (a targeted cancer drug) works in Korean patients with specific types of lung cancer or solid tumors. You'd be monitored after starting this medication to help doctors understand how it affects people over time.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.